Pharma BD Deal Intelligence
Boehringer Ingelheim acquired Swiss biotech T3 Pharmaceuticals AG for up to CHF 450M (~$508M), gaining T3P-Y058-739, a Phase 1/2 engineered live-bacterial cancer therapy for advanced solid tumors. The asset is a genetically-modified, live attenuated strain of Yersinia enterocolitica that uses the bacterial type III secretion system to micro-inject immunomodulatory proteins (RIG-I CARD and cGAS, driving type I interferon production) directly into the tumor microenvironment while sparing healthy tissue. The buyout, which builds on a research collaboration running since 2018, deepens Boehringer's cancer-immunology portfolio with a non-checkpoint platform modality. Upfront undisclosed; milestone-based portion ~$268M. As of April 2026 the first-in-human study (NCT05120596) remained recruiting, evaluating intratumoral and intravenous monotherapy plus a pembrolizumab combination, with primary completion estimated for early 2027.